Status | Study |
Recruiting |
Study Name: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Condition: Breast Cancer Cholangiocarcinoma Colorectal Cancer Date: 2015-10-02 Interventions: Drug: Entrectinib TrkA/B/C, ROS1, and ALK inhibitor |
Recruiting |
Study Name: Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Condition: Anaplastic Large Cell Lymphoma, ALK-Negative Date: 2015-09-24 Interventions: Drug: Cyclophosphamide Given I |
Recruiting |
Study Name: CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Condition: Peripheral T-Cell Lymphoma Angioimmunoblastic T Cell Lymphoma Date: 2015-07-18 Interventions: Drug: CEOP/IVE/GDP chemotherapy regimen |
Withdrawn |
Study Name: A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Condition: Systemic Anaplastic Large-Cell Lymphoma Date: 2015-06-30 Interventions: Drug: crizotinib crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vinc |
Recruiting |
Study Name: Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL Condition: ALK+ Anaplastic Large Cell Lymphoma Date: 2015-05-18 Interventions: Drug: Brentuximab vedotin Bren |
Recruiting |
Study Name: Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas Condition: Anaplastic Large Cell Lymphoma, ALK-Positive Date: 2015-04-03 Interventions: Drug: crizotinib |
Recruiting |
Study Name: CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) Condition: Lymphomas Date: 2014-10-22 Interventions: Genetic: Anti-CD30 CAR T cells Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR |
Recruiting |
Study Name: Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Condition: Non-Hodgkin Lymphoma Date: 2014-10-05 Interventions: Drug: Brentuximab vedotin Brentuximab vedotin must not be administered as an IV push or bolus. It must b |
Recruiting |
Study Name: Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Condition: Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell L Date: 2014-09-03 Interventions: Drug: romidepsin Given IV |
Recruiting |
Study Name: Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study Condition: Peripheral T-cell Lymphomas (PTCL) PTCL-NOS Angioimmunobla Date: 2014-07-21 Interventions: Drug: Ro-CHOEP-21 (PHASE I) |